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Key Points
• Ibrutinib added to 10-day
decitabine does not
improve response or
survival in newly diag-
nosed AML patients
unsuitable for intensive
chemotherapy.
•Mutated TP53 corre-
lates with high re-
sponse and STAG2/
IDH2/ASXL1 with low
response rates.
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based
on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib
cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the
tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in unfit (ie,
Hematopoietic Cell Transplantation Comorbidity Index $3) AML patients and higher risk
myelodysplasia patients (HOVON135/SAKK30/15 trial). In total, 144 eligible patients were
randomly (1:1) assigned to either 10-day decitabine combined with ibrutinib (560 mg;
sequentially given, starting the day after the last dose of decitabine) (n 5 72) or to 10-day
decitabine (n 5 72). The addition of ibrutinib was well tolerated, and the number of adverse
events was comparable for both arms. In the decitabine plus ibrutinib arm, 41% reached
complete remission/complete remission with incomplete hematologic recovery (CR/CRi), the
median overall survival (OS) was 11 months, and 2-year OS was 27%; these findings compared
with 50% CR/CRi, median OS of 11.5months, and 2-year OS of 21% for the decitabine group (not
significant). Extensivemolecular profiling at diagnosis revealed that patientswith STAG2, IDH2,
and ASXL1mutations had significantly lower CR/CRi rates, whereas patients with mutations in
TP53 had significantly higher CR/CRi rates. Furthermore, multicolor flow cytometry revealed
that after 3 cycles of treatment, 28 (49%) of 57 patients with available bone marrow samples
had no measurable residual disease. In this limited number of cases, measurable residual
disease revealed no apparent impact on event-free survival and OS. In conclusion, the addition
of ibrutinib does not improve the therapeutic efficacy of decitabine. This trial was registered at
the Netherlands Trial Register (NL5751 [NTR6017]) and has EudraCT number 2015-002855-85.
Submitted 2 July 2020; accepted 17 July 2020; published online 10 September 2020.
DOI 10.1182/bloodadvances.2020002846.
All requests for data sharing should be sent to the corresponding author (Gerwin Huls;
e-mail: g.huls@umcg.nl).
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
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Introduction
About 75% of patients with acute myeloid leukemia (AML) are
aged $60 years.1 The optimal treatment of older AML patients
in daily clinical practice remains challenging and is dependent
on patient characteristics (ie, age, performance, comorbidities),
disease characteristics (ie, cytogenetic and molecular abnormal-
ities, white blood cell [WBC] count), and the preference of the
patient.2 The hypomethylating agents (HMAs) azacitidine and
decitabine have relatively mild side effects and are particularly feasible
for the treatment of older patients and patients with comorbidities.
Although not in their primary analyses, recent phase 3 trials have
shown the superiority of azacitidine and decitabine compared
with conventional care for older patients with AML in a prespe-
cified analysis (censoring patients who received AML treatment
after discontinuing study drug [azacitidine]) or after an unplanned
analysis (after more events [decitabine]).3-5 Results of treatment
with modifications of the standard azacitidine (7 days, 75 mg/m2
subcutaneously; every 4 weeks) and decitabine (5 days, 20 mg/m2
IV; every 4 weeks) schedules have been reported. Initial studies
evaluating the 10-day decitabine schedule have shown promising
results. In a hallmark study, 52 older patients newly diagnosed
with AML were treated with the 10-day decitabine schedule; 21
patients (40%) achieved a complete remission (CR), and the
median overall survival (OS) was 318 days.6 Various retrospective
analyses have confirmed these favorable data.7,8 A phase 3 trial
(#NCT02172872) in older patients with AML (aged$60 years) that
compares conventional intensive chemotherapy based on cytarabine
combined with an anthracycline (“31 7”) with the 10-day decitabine
schedule, followed by allogeneic hematopoietic cell transplantation,
is currently in progress.
It remains an important clinical challenge to further improve the
cumulative CR/complete remission with incomplete hematologic
recovery (CR/CRi) rates and survival of the 10-day decitabine
schedule. Based on preclinical scientific evidence, we hypothesized
that ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK) that is
approved by the US Food and Drug Administration for the treatment
of mantle cell lymphoma, chronic lymphocytic leukemia, and
Waldenström macroglobulinemia, could be an interesting new drug
to add to decitabine.9 Although BTK is critical to the B-cell receptor
signaling cascade, AML cell lines also have high expression of BTK,
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Figure 1. Study scheme. BM, bone marrow; D, day.
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comparable to B-cell lines (www.broadinstitute.org/ccle). It has
been reported that BTK is phosphorylated in the leukemic blasts in
.90% of AML patient samples but not in healthy CD341 cells.10-12
Furthermore, it seems that ibrutinib (alone or combined with
cytarabine or daunorubicin) inhibits blast proliferation from human
AML in vitro.10 The in vitro cytotoxicity of ibrutinib in AML is
comparable to the in vitro cytotoxicity of primary chronic lympho-
cytic leukemia cells (ie, 50% inhibitory concentration of ;5 mM).
BTK-targeted RNA interference knockdown reduces colony-
forming capacity of primary AML blasts and proliferation of AML
cell lines. Silencing of BTK inhibits protein kinase B (AKT) and
extracellular signal-regulated kinase (ERK) pathways in AML cells. It
has been shown that ibrutinib’s antiproliferative effects in AML are
mediated via an inhibitory effect on downstream NF-kB survival
pathways.11 Moreover, ibrutinib seems to inhibit AML cell adhesion
to bone marrow stroma.13 These experimental results provide
a biological rationale for the clinical evaluation of BTK inhibition
in patients with AML.
Here we present the final analysis of the HOVON135/SAKK-30/15
study. In this phase 2 study, older patients (aged$66 years) with AML
or higher risk myelodysplasia (MDS) (Revised International Prognostic
Scoring System score .4.5) considered not suitable for intensive
cytotoxic treatment were randomized to receive 10-day decitabine
with or without ibrutinib. The aim was to assess the value of adding
ibrutinib to 10-day decitabine with respect to CR/CRi after 3 cycles of
treatment (primary end point) and OS (secondary end point).
Methods
Study design, patients, and treatment
This was a randomized phase 2 multicenter study (HOVON135;
SAKK30/15; EudraCT #2015-002855-85) (protocol is available
at: www.hovon.nl). Previously untreated adults who were$66 years
old and not considered eligible for intensive chemotherapy, with
a cytopathologically confirmed diagnosis of AML or with higher
risk MDS (Revised International Prognostic Scoring System
score .4.5), a World Health Organization (WHO) performance
status #2, and written informed consent, were eligible. Patients
were considered not suitable for intensive chemotherapy if they
had comorbidities that would put them at high risk for early
death when treated with intensive chemotherapy (defined as
hematopoietic cell transplantation comorbidity index [HCT-CI]
$3) or if the patient declined to receive intensive chemotherapy.
The limit for HCT-CI $3 was chosen because this value has
been shown to be associated with an early mortality rate (,30
days) of ;30% in older patients with AML who are treated with
intensive chemotherapy.14 Based on the karyotype and molec-
ular genotype of the leukemic cells, patients were classified into
prognostic categories according to the European LeukemiaNet
(ELN) 2017 criteria.15
Patients were randomly assigned (1:1) to 10-day decitabine without
(arm A) or with (arm B) ibrutinib 560 mg (Figure 1). In arm B,
ibrutinib was given sequentially with decitabine, starting the day
after the last dose of decitabine until the day before the start of the
next cycle of decitabine. (Decitabine and ibrutinib were provided
free of charge by Janssen Pharmaceutics.) The duration of
decitabine in the second and third cycle (ie, 5 or 10 days) was
dependent on the percentage of bone marrow blasts (ie, ,5%
or $5%), as determined by cytomorphology, at the day 28 bone
marrow evaluation. Cycle 2 started within 1 week after the day
28 bone marrow evaluation, independent of recovery of peripheral
counts. Cycle 3 started if neutrophils were $0.5 3 109/L or
platelets were $25 3 109/L, with a maximum delay of 2 weeks.
From cycle 4, treatment could only be continued with 5-day
decitabine (with or without ibrutinib).
Molecular analyses and flow cytometry
Bone marrow aspirations or peripheral blood samples at di-
agnosis were taken. Blasts and mononuclear cells at diagnosis
were purified by Ficoll-Hypaque (Nygaard, Oslo, Norway) density
gradient centrifugation and cryopreserved. After thawing, cells
were lysed in RLT solution with the addition of dithiothreitol
(Qiagen, Venlo, The Netherlands). High-quality DNA and RNA
were extracted by using QIAsymphony (Qiagen). DNA concentration
was measured by Qubit Fluorometric Quantitation (Thermo Fisher
Scientific, Wilmington, DE) and RNA concentration using the Implen
NanoPhotometer (Westburg, Leusden, The Netherlands). CBFB-
MYH11, RUNX1-RUNX1T1, and FLT3 internal tandem duplication
mutations were determined as previously described.16,17 Mutations
in 38 of 54 genes frequently mutated in hematologic malignancies
were determined by targeted next-generation sequencing (NGS)
with the TruSight Myeloid Sequencing panel, following the
manufacturer’s protocol (Illumina, San Diego, CA). The NGS
libraries were paired-end sequenced (2 3 221 bp) on a MiSeq
System (Illumina). Variants were called as described.18
Residual disease detection by using multiparameter flow cytom-
etry was performed as previously described.19 The residual
disease percentage was defined as the number of leukemia-
associated immunophenotype (LAIP) cells within the bone
marrow compartment. The threshold between residual and no
Table 1. Patient characteristics
Characteristic
10-d decitabine
(n 5 72)
10-d decitabine 1 ibrutinib
(n 5 72)
Sex, male/female 47/25 (65/35) 42/30 (58/42)
Age, median (range), y 76 (68-84) 75 (66-89)
WHO performance
WHO 0 26 (36) 25 (35)
WHO 1 38 (53) 35 (49)
WHO 2 8 (11) 12 (17)
Comorbidity
HCT-CI 0-2 42 (58) 42 (58)
HCT-CI $3 30 (42) 30 (42)
ELN risk group (AML)
Favorable 15 (21) 10 (14)
Intermediate 12 (17) 11 (15)
Adverse 34 (47) 37 (51)
Unknown 0 (0) 2 (3)
Primary AML 48 (67) 45 (63)
Secondary AML 13 (18) 15 (21)
MDS 11 (15) 12 (17)
WBC, median (range), 3109/L 2.95 (0.70-29.9) 3.20 (0.60-30.0)
Data are n (%) except as noted.
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residual disease based on flow cytometry was established and
validated on 0.1%.19,20 Information on clones and commercial
sources of all monoclonal antibodies used is provided in
supplemental Table 1.
Study end points and statistical analysis
The aim of this study was to decide whether the addition of ibrutinib
to standard induction treatment could be sufficiently effective to
warrant continuation to a phase 3 study. The observed difference in
CR/CRi rates between investigational arm B and standard arm A
was used as the criterion in decision rules. At final analysis, the
decision to stop because of inefficacy (ie, not to continue with
phase 3) was based on observed difference in CR/CRi rates#0 or
if the upper limit of the 80% confidence interval (CI) was ,25%.
The primary end point of the study was cumulative CR/CRi after 3
cycles (for all patients [MDS and AML]). A patient was considered to
have a CR/CRi if this end point was attained within the first 3 induction
cycles and the patient did not relapse on a consecutive cycle (within
these 3 induction cycles). All other patients without “CR/CRi after 3
cycles” (including partial remission and morphologic leukemia-free
state [MLFS]) were classified as “induction failures.”
Secondary end points included safety, tolerability, and efficacy
profile (response rate [CR, CRi, MLFS, partial remission]), event-
free survival (EFS), and OS. OS is defined as the time from the date
of randomization to the date of death, whatever the cause. The
follow-up of patients still alive was censored at the moment of last
visit/contact. EFS was defined as the time from registration to
induction failure, death, or relapse, whichever occurred first. Kaplan-
Meier survival curves and Cox regression tests were used to
compare the survival distributions between the treatment arms. For
statistical comparison of mutation frequencies and clonal character-
istics between individuals with and without a response, Fisher’s
exact test and Mann-Whitney U tests were used.
Results
Study patients and treatment
From 1 September 2016 until 13 June 2018, a total of 144 patients
were registered for the study. The database was closed on 17
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Figure 2. CONSORT study diagram. Arm A 5 10-day decitabine; arm B 5 10-day decitabine plus ibrutinib. PD, progressive disease; Tx, treatment.
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February 2020. The median follow-up for all patients is 11.3 months,
and the median follow-up for patients still alive is 23.5 months.
Patient characteristics are described in Table 1. The main patient-
related factors (sex, age, performance, and comorbidities) and
disease-related factors (2017 ELN risk, secondary AML, MDS, and
WBC count) were equally distributed over both arms. In the
decitabine arm (arm A), 65% were male, median age was 76 years
(range, 68-84 years), 89% had performance score WHO 0 to 1,
and 42% had an HCT-CI $3. In the decitabine plus ibrutinib arm
(arm B), 58% were male, median age was 75 years (range, 66-89
years), 84% had performance score WHO 0 to 1, and 42% had an
HCT-CI $3. In arm A, 47% had 2017 ELN adverse risk and 18%
secondary AML; in arm B, 53% had 2017 ELN adverse risk and
21% secondary AML.
All 72 patients allocated to arm A started 10-day decitabine; 59
patients (82%) received a second cycle, and 48 patients (67%)
received a third cycle. In arm B, 2 patients (of 72) went off
protocol before the start of the first 10-day decitabine cycle; 51
patients (82%) received a second cycle, and 39 patients (54%)
received a third cycle. Main reasons to discontinue treatment
were death, adverse events (AEs) preventing further treatment,
and progressive disease/relapse (Figure 2). “Full-dose” decitabine
(including “delayed”) was given in arm A in 99%, 97%, and 98%
and in arm B in 100%, 92%, and 92% in the first 3 cycles. The full-
dose ibrutinib was given in 53%, 45%, and 38% during the first 3
cycles; “dose reduced .10%” and/or “delayed” in 38%, 33%, and
44% during the first 3 cycles; “interrupted and resumed” in 6%,
12%, and 5% during the first 3 cycles; and “not given” in 3%, 10%,
and 13% during the first 3 cycles. The relatively high number of
patients whose dose was “reduced by .10%” and/or “delayed”
might be explained by the study protocol, which required reducing
the dose of ibrutinib from 560 mg to 140 mg in case moderate or
strong cytochrome P450 3A inhibitors were used (eg, ciprofloxacin,
posaconazole, voriconazole). The median number of decitabine
cycles applied was 4 in arm A (range, 1-26) and 3 (range, 1-29) in
arm B. Three patients received an allogeneic hematopoietic cell
transplantation (1 in arm A, 2 in arm B).
Treatment outcome according to randomization
The primary end point of this study was the cumulative CR/CRi rate
during the first 3 cycles, which was attained in 29 of 72 patients
(40%; 80% CI, 33-48) in arm A and 22 of 72 patients (31%; 80%
CI, 24-38) in arm B. Thus, there is no difference in CR/CRi between
arms B and A. Some patients obtained a CR/CRi after the first 3
cycles (the primary end point), resulting in a total CR/CRi rate (on
protocol) of 50% in arm A and 41% in arm B.
At time of the final analysis, a total of 116 patients had died. Median
OS was 11.5 months in arm A and 11.0 months in arm B. OS at 12
and 24 months was similar between arms (A vs B): 47% (95% CI,
35-58) vs 49% (95% CI, 37-60) and 21% (95% CI, 12-31) vs 27%
(95% CI, 17-38), respectively (log-rank test, P 5 .48) (Figure 3).
The CR/CRi rates within the first 3 cycles were 40% for favorable,
35% for intermediate, and 35% for adverse risk AML according to
ELN 2017 criteria, and 35% for the higher risk MDS patients. The
OS was not different for the favorable, intermediate, and adverse
risk AML and higher risk MDS subgroups (log-rank test, P 5 .08)
(supplemental Figure 1).
Tolerability of treatment
During cycle 1, the median number of nights in the hospital was 13
(range, 0-42) in arm A and 17 (range, 0-56) in arm B; during cycle 2,
the median number of nights in the hospital was 9 (range, 0-32) in
arm A and 10 (range, 0-33) in arm B (Table 2). During the third
cycle, the median number of nights in the hospital for both arms was
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Figure 3. Kaplan-Meier estimates for OS. Arm A 5 10-
day decitabine arm; arm B 5 10-day decitabine plus ibruti-
nib. Median OS was almost 12 months in both arms.
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0. The median number of red blood cell transfusions in arms A and
B were comparable: 5, 4, and 2, respectively, during cycles 1, 2, and
3. The median number of platelet transfusions in arms A and B was
also comparable: 3, 1, and 0 during cycles 1, 2, and 3.
The total number of grade 2 to 4 AEs was 577 (72 of which were
serious AEs) in arm A and 524 (72 of which were serious AEs) in
arm B (supplemental Table 2). The number of any Common
Terminology Criteria for Adverse Events grade 2, 3, or 4 AEs was
9%, 14%, and 5% in arm A and 11%, 18%, and 4% in arm B,
respectively. Grade 3/4 infections and infestations were 9% in both
arms. The early death rate (within 30 days from registration) was
13% in arm A and 3% in arm B.
Treatment outcome according to molecular profile
Comprehensive molecular analysis at diagnosis was performed
in 140 cases; 7 (5%) of these had no detectable gene mutations.
The most frequently mutated genes were DNMT3A (33%), TET2
(26%), ASXL1 (25%), SRSF2 (24%), RUNX1 (23%), and TP53
(19%) (Table 3). The typical molecular abnormalities in (younger)
AML, mutated NPM1 and FLT3 internal tandem duplication, were
both observed in only 14% of these older patients. The various
mutations were generally equally distributed over both treatment
groups (supplemental Figure 3A).
The response rates (CR/CRi) after 3 cycles of treatment were not
different for most of the molecular abnormalities (supplemental
Figure 3B). The response rates (CR/CRi within 3 cycles) for the
most frequently mutated genes in the evaluable 140 patients are
depicted in Table 3. Of those mutations that were observed at least
10 times, only mutations in TP53were associated with a significantly
higher CR/CRi rate (56%) during the first 3 cycles (Figure 4A). This
favorable CR/CRi rate did not translate into superior OS of patients
with mutated TP53 (supplemental Figure 4). Indeed, the inferior OS
of patients with mutated TP53 was borderline significant compared
with those without mutated TP53 (P 5 .05). Among the mutations
that were observed at least 10 times, patients with mutations in
STAG2, IDH2, and ASXL1 showed significantly reduced CR/CRi
rates within 3 cycles of decitabine (12% for STAG2, 17% for IDH2,
and 20% for ASXL1). Although numbers were low, the reduced
CR/CRi rates for these genes did not result in inferior OS of
patients with these genes mutated (supplemental Figure 5).
In addition, to address the question of whether the size of the
(dominant) clone or the number of (sub) clones affects response to
decitabine, we analyzed the relation between variant allele
frequency, the number of mutations, and outcome. This analysis
revealed that the highest variant allele frequency per individual, the
number of mutations per individual (median, 3; range, 0-12), and the
number of mutated genes per individual (median, 3; range, 0-9) did
not correlate with CR/CRi rates within 3 cycles (Figure 4B-D). With
respect to the most common cytogenetic abnormalities, only the
presence of complex cytogenetic abnormalities (ie,$3) was associated
with a greater probability of response (Figure 4A).
Treatment outcome according to minimal
residual disease
LAIP was determined by multiparameter flow cytometry in all 144
patients using bone marrow samples before the start of study
Table 2. Tolerability of treatment per treatment arm
Variable
10-d decitabine
(n 5 72)
10-d decitabine 1 ibrutinib
(n 5 72)
Cycle 1, median
Nights in hospital 13 17
No. of RBC transfusions 5 5
No. of platelet transfusions 3 3
Cycle 2, median
Nights in hospital 9 10
No. of RBC transfusions 4 4
No. of platelet transfusions 1 1
Cycle 3, median
Nights in hospital 0 0
No. of RBC transfusions 2 2
No. of platelet transfusions 0 0
AEs, any, n (%)
Grade 2 50 (9) 58 (11)
Grade 3 81 (14) 92 (18)
Grade 4 30 (5) 21 (4)
Patients with SAEs, n (%)
0 SAE 14 (19) 9 (13)
1 SAE 25 (35) 32 (44)
2 SAEs 12 (17) 21 (29)
3 SAEs 13 (18) 6 (8)
.3 SAEs 8 (11) 4 (6)
RBC, red blood cell; SAE, serious AE.
Table 3. Molecular diagnostics and response
Gene
No. of individuals
with mutations
No. (%) CR/CRi
after 3 cycles
DNMT3A 46 18 (39)
TET2 36 10 (28)
ASXL1 35 7 (20)
SRSF2 34 8 (24)
RUNX1 32 9 (28)
TP53 27 15 (56)
IDH2 23 4 (17)
NRAS 21 8 (38)
NPM1 19 5 (26)
STAG2 17 2 (12)
U2AF1 15 8 (53)
SF3B1 15 6 (40)
JAK2 12 6 (50)
BCOR 12 5 (42)
EZH2 11 2 (18)
CEBPA 10 2 (20)
FLT3 10 4 (40)
Data from 140 patients with available extensive molecular analyses are considered.
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treatment. Minimal residual disease (MRD) was assessed in
bone marrow samples after cycle 3 in 57 patients, of whom 42
were in CR/CRi/MLFS (34 in CR/CRi; 8 in MLFS). Median MRD
was 0.12% (range, 0%-47.9%). Of these 57 patients, 28 (49%)
became MRD negative (,0.1% LAIP/WBC count). Interest-
ingly, the EFS and OS curves of these 57 patients were
independent of their MRD status (positive, n5 29; negative, n5
28) (Figure 5). Also, when only considering the 34 patients in
CR/CRi or the 42 patients in CR/CRi/MLFS, the OS was
independent of MRD status (supplemental Figure 6). Although
the 0.1% threshold was not able to identify patients with superior
survival, lowering the cutoff point to 0.05% (resulting in 3 more
MRD-positive patients) was not able to discriminate OS between
patients with and without MRD.
Discussion
HMAs are an important treatment modality in older, unfit
patients with AML and in higher risk MDS patients. Here we
report on the therapeutic value of ibrutinib added to 10-day
decitabine regimen. Recent preclinical insights regarding the
inhibitory effects of ibrutinib on AML blasts led us to perform
a randomized phase 2 clinical trial in older patients with newly
diagnosed AML. However, this study, which compared a 10-day
decitabine schedule with a combination of decitabine plus ibrutinib,
revealed no therapeutic advantage for the ibrutinib combination.
No improvement in response was noted for the ibrutinib arm.
The results of the study also did not suggest indications for
a therapeutic benefit in a particular molecular subset of AML (eg,
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Figure 4. Associations between molecular and cytogenetic abnormalities (with prevalence ‡10) and response. (A) The association between individual frequently
mutated genes ($10 times) and frequently observed cytogenetic abnormalities ($10 times) and response (CR/CRi) after 3 cycles. Odds ratios are displayed on a log10 scale,
with lines extending to the 95% CI. Horizontal bars indicate the proportion with a mutation in the respective gene for patients with (blue) and without (red) response, with
absolute numbers given for each gene. Data on molecular abnormalities were available for 140 individuals, whereas cytogenetic abnormalities were assessed in a subset of
114 individuals with identified cytogenetic abnormalities. P values are derived from Fisher’s exact test. The association between response (CR/CRi) within 3 cycles and highest
variant allele frequency (VAF) per individual (B), number of mutations per individual (C), and number of mutated genes per individual (D). P values are from Wilcoxon signed-
rank test.
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those with mutated CSF3R or FLT-3). In a previously reported,
small, open-label, phase 2a study (n 5 36) (accrual between
February 2015 and April 2017), ibrutinib alone or in combination
with cytarabine or azacitidine had also shown limited antileukemic
efficacy.21
Although ibrutinib did not improve the CR/CRi rate (which was
the primary end point of the study), this prospective randomized
trials shows that 10-day decitabine offers valuable antileuke-
mic activity with a median OS of almost 12 months in this older,
unfit patient population. This median OS is comparable with the
previously reported median OS that was achieved in so-called
fit AML patients of older age with intensive chemotherapy in
the HOVON43 study.22 The current outcome data compare
favorably with other open-label randomized trials using decita-
bine, which had a reported median OS of 7.7 months (95% CI,
6.2-9.2) with the 5-day decitabine schedule and 9.3 months
(95% CI, 5.8-12.2) with the 10-day schedule.5,23 Although direct
comparisons of outcome data across different studies do not allow
robust conclusions, the good adherence to the protocol, including
start of the second cycle ,1 week (independent of peripheral
counts) and relatively high number of median cycles of decitabine
applied, could have contributed to the comparatively favorable
outcome.
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Figure 5. Kaplan-Meier estimates of EFS and OS. Graphs depict
data from all 57 patients with available MRD data after 3 cycles.
4274 HULS et al 22 SEPTEMBER 2020 x VOLUME 4, NUMBER 18
D
ow
nloaded from
 http://ashpublications.org/bloodadvances/article-pdf/4/18/4267/1757860/advancesadv2020002846.pdf by guest on 26 O
ctober 2020
As for the study reported here, previous randomized trials failed to
show a benefit for additions to HMA with histone deacetylase
inhibitors (including entinostat, valproic acid, vorinostat, and
pracinostat) and the immune modulating agent lenalidomide and
the proteasome inhibitor bortezomib.23-29 Other agents such as
selective inhibitors of isocitrate dehydrogenase 1 (ivosidenib) and 2
(enasidenib) in combination with HMAs are currently in advanced
clinical testing. The combination of HMA with venetoclax seems to
be the first combination that indeed improves outcomes when
added to single-agent HMA. The pivotal phase 1b trial evaluating
the combination venetoclax plus HMA in untreated AML of the
elderly reported acceptable tolerance with high response rates
(composite CR rate, 73%).30 In that study, 400 mg of venetoclax
seemed to have the best safety profile while providing deep and
durable responses in a poor-risk population. The VIALE-A study
(#NCT02203773), a randomized phase 3 trial comparing azaciti-
dine plus placebo vs azacitidine plus venetoclax, confirmed the
additive value of venetoclax added to azacitidine by a significant
increase in the CR/CRi rate from 28% to 66% and a significant
increase in median OS from 9.6 months to 14.7 months.31
In our cohort of 144 patients, we were able to identify an association
between mutational status and CR/CRi during the first 3 cycles. Of
the more frequent mutations (ie, observed$10 times), only mutated
TP53 was associated with a significantly higher CR/CRi rate,
confirming the previously reported favorable response of TP53
mutated AML to HMA.32,33 In contrast to previously published data,
in retrospective and smaller cohorts, we could not confirm that
mutations in TET2, DNMT3A, and IDH1/2 are associated with higher
response rates after treatment with HMA.34-36 Mutated STAG2, IDH2,
and ASXL1 were significantly associated with lower CR/CRi rates
during the first 3 cycles. In the VIALE-A study, a low CR/CRi rate after
treatment with azacitidine was also observed in patients with IDH
mutations, which could partially explain the favorable hazard ratio for
azacitidine plus venetoclax compared with azacitidine alone for patients
with IDHmutations in the VIALE-A study (ie, 0.28 for IDH1 and 0.34 for
IDH2-mutated AML).31 Lower CR rates to azacitidine in patients with
IDH2 or STAG2 mutations were also observed in a cohort of 250
patients with newly diagnosed, relapsed, or refractory AML or high-risk
MDS patients.27 Although the associations with mutated TP53, IDH2,
and STAG2 become more solid, in general, the different associations
between mutational status and outcome might be explained by the
limited numbers, the interaction between the various mutations, and by
the heterogeneity of the leukemia within each patient. Finally, although
it has been suggested that HMAs are particularly effective against
subclones (in contrast to founder clones), it could be hypothesized that
the size of the dominant clone or the number of (sub) clones (reflected
by the number of mutations) could affect outcome,37,38 although our
data did not show this.
In general, responses to HMAs are rarely sustained and have a weak
correlation with OS.3-5 Although patients who obtain CR/CRi have
a superior OS compared with patients who do not obtain CR/CRi (in
our cohort,.12 months longer median OS) (supplemental Figure 2),
limited data are available on how the depth of response after HMA
correlates with outcome. Our data show that a good quality response,
reaching MRD negativity, may be achieved with the 10-day decitabine
schedule (49% of the patients after cycle 3). In a cohort of 115
patients with AML treated with various HMAs, of whom 61 patients
(53%) had evaluable MRD data at the time of response, 25 (41%)
became MRD negative, with no impact on OS.39 In line with these
data, in our cohort, MRD negativity did not predict for OS either. This
outcome seems discrepant from treatment with intensive chemotherapy
in older patients with AML, in whom assessment of treatment response
using flow cytometry provides powerful independent prognostic
information.40 The clonal dynamics and the predictive value of MRD
determined by flow cytometry (and likely NGS) in the context of
treatment with intensive chemotherapy and HMA may be different. The
relatively mild impact of HMAon founder clones could be an explanation
for this difference.37,38
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2. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767-774.
3. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low
bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
4. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed
AML with .30% blasts. Blood. 2015;126(3):291-299.
5. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician
advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol.
2012;30(21):2670-2677.
6. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of
decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473-7478.
7. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;
54(9):2003-2007.
8. Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for
intensive chemotherapy. Leuk Lymphoma. 2014;55(7):1533-1537.
9. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54(11):2385-2391.
10. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid
leukemia. Blood. 2014;123(8):1229-1238.
11. Pillinger G, Abdul-Aziz A, Zaitseva L, et al. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. Sci Rep. 2015;5(1):12949.
12. Dwivedi P, Muench DE, Wagner M, et al. Time resolved quantitative phospho-tyrosine analysis reveals Bruton’s tyrosine kinase mediated signaling
downstream of the mutated granulocyte-colony stimulating factor receptors. Leukemia. 2019;33(1):75-87.
13. Zaitseva L, Murray MY, Shafat MS, et al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget. 2014;5(20):9930-9938.
14. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients
over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624-627.
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